Head-To-Head Review: Osiris Therapeutics (OTCMKTS:OSIR) & Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI) and Osiris Therapeutics (OTCMKTS:OSIR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Profitability

This table compares Dyadic International and Osiris Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyadic International	-188.09%	-149.16%	-59.81%
Osiris Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are held by institutional investors. 28.8% of Dyadic International shares are held by company insiders. Comparatively, 43.4% of Osiris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Dyadic International and Osiris Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.36 million	12.14	-$6.80 million	($0.23)	-6.00
Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A

Osiris Therapeutics has lower revenue, but higher earnings than Dyadic International.

Analyst Ratings

This is a summary of current ratings and price targets for Dyadic International and Osiris Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	0	0	1	0	3.00
Osiris Therapeutics	0	0	0	0	0.00

Dyadic International presently has a consensus price target of $6.00, indicating a potential upside of 334.78%. Given Dyadic International’s stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Osiris Therapeutics.

Summary

Dyadic International beats Osiris Therapeutics on 5 of the 9 factors compared between the two stocks.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

About Osiris Therapeutics

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.